期刊文献+

氟尿嘧啶和亚叶酸联合奥沙利铂和伊立替康方案治疗17例晚期结直肠癌临床分析 被引量:2

下载PDF
导出
摘要 目的评价氟尿嘧啶和亚叶酸钙联合伊立替康和奥沙利铂治疗晚期结直肠癌患者的有效性和安全性。方法选择晚期结直肠癌患者先静脉滴注伊立替康165mg/m2(1h),再静脉滴注奥沙利铂85mg/m2和亚叶酸400mg/m2(2h),然后持续静脉滴注氟尿嘧啶2400mg/m2(48h),每14d为一周期。结果 17例患者入组,无CR病例,PR9例(52.9%),SD6例(35.3%)。最常见的Ⅲ、Ⅳ级毒副反应是中性粒细胞下降(58.8%)。结论此联合方案治疗晚期结直肠癌患者具有良好的疗效和耐受性。
出处 《福建医药杂志》 CAS 2010年第3期124-126,共3页 Fujian Medical Journal
基金 福建省卫生厅青年科研项目基金(2007-1-34)
  • 相关文献

参考文献7

  • 1Tournigand C,Andre T,Achille E,et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study[J].J Clin Oncol,2004,22(2):229-237.
  • 2Grothey A,Sargent D,Goldberg RM,et al.Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin,irinotecan,and oxaliplatin in the course of treatment[J].J Clin Oncol,2004,22 (7):1209-1214.
  • 3林榕波,郭增清,陈奕贵,范南峰,王晓杰,陈帆,刘捷,林锦源.西妥昔单抗联合伊立替康治疗化疗耐药晚期结直肠癌[J].中国癌症杂志,2008,18(1):79-80. 被引量:19
  • 4Correale P,Cusi MG,Tsang KY,et al.Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients[J].J Clin Oncol,2005,23 (35):8950-8958.
  • 5Lim HJ,Gill S,Speers C,et al.Impact of Irinotecan and Oxal iplatin On Overall Survival in Patients With Metastatic Colorectal Cancer:A Population-Based Study[J].J Oncol Pract,2009,5(4):153-158.
  • 6Souglakos J,Androulakis N,Syrigos K,et al.FOLFOXIRI(folinic acid,5-fluorouracil,oxaliplatin and irinotecan) VS FOLFIRI (foiinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG)[J].Br J Cancer,2006,94 (6):798-805.
  • 7Falcone A,Ricci S,Brunetti I,et al.Phase Ⅲ trial of infusional fluorouracil,leucovorin,oxaliplatin,and irinotecan (FOLFOXIRI) compared with infusional fluorouracil,leucovorin,and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:the Gruppo Oncologico Nord Ovest[J].J Clin Oncol,2007,25 (13):1670-1676.

二级参考文献10

  • 1钱军,秦叔逵,曹梦苒,邵志坚,成远,吴成利.西妥昔单抗联合伊立替康为主方案治疗耐药性晚期结直肠癌的临床观察[J].中国癌症杂志,2007,17(1):29-31. 被引量:6
  • 2Saltz LB, Meropol N J, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [ J ]. J Clin Oncol, 2004,22 : 1201-1208.
  • 3Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004,351:337-345.
  • 4Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[ J]. J Clin Oncol, 2006,24:4914-4921.
  • 5Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor ( EGFR ) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies [J]. J Clin Oncol, 2004,22:4772-4778.
  • 6Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [ J ]. J Clin Oncol, 2005,23 : 1803-1810.
  • 7Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [ J ]. Cancer Res, 2006,66:3992-3995.
  • 8Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor ( EGFR ) and clinical response to antiEGFR treatment in coloreetal cancer: a cohort study [ J ]. Lancet Oncol, 2005,6:279-286.
  • 9Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab [ J ]. J Clin Oncol, 2007,25:3712-3718.
  • 10Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy[ J]. J Clin Oncol, 2007,25:3930-3935.

共引文献18

同被引文献18

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部